Barbara Klencke, Director at TScan Therapeutics, Inc. (TCRX), bought 5,000 shares at $5.29 ($26K) on 2024-09-23, disclosed to the SEC on 2024-09-24.
Open-market purchase of $26k TCRX by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Something here stands out, but not much.
| Filing → |
| SRRA | BUY | 2020-08-18 | $113K | — | Filing → |
| SRRA | BUY | 2019-08-26 | $101K | — | Filing → |